UNIGE document Scientific Article
previous document  unige:72647  next document
add to browser collection
Title

Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation

Authors
Dubois, D
Rothmeier, C
Published in Chest. 1999, vol. 116, no. 5, p. 1265-72
Abstract Cytomegalovirus (CMV) disease is one of the major challenges of lung transplantation that may determine outcome. The benefits of ganciclovir prophylaxis seem indisputable, but no consensus has been reached on the optimal duration of therapy. Results with different protocols suggest that efficacy is related to the duration of treatment.
Keywords AdolescentAdultAntibiotic Prophylaxis/economics/methodsAntibodies, Viral/analysisAntiviral Agents/administration & dosage/economics/therapeutic useBronchoalveolar Lavage Fluid/virologyChildCost-Benefit AnalysisCosts and Cost AnalysisCytomegalovirus/immunology/isolation & purificationCytomegalovirus Infections/economics/epidemiology/prevention & control/virologyFemaleFollow-Up StudiesGanciclovir/administration & dosage/economics/therapeutic useGraft Rejection/immunology/prevention & controlHumansImmunosuppressive Agents/therapeutic useIncidenceInfusions, IntravenousLung TransplantationMaleMiddle AgedPneumonia, Viral/economics/epidemiology/prevention & control/virologyProspective StudiesSurvival RateSwitzerland/epidemiologyTreatment Outcome
Identifiers
PMID: 10559085
Full text
Article (Published version) (176 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Citation
(ISO format)
GERBASE, Margaret et al. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation. In: Chest, 1999, vol. 116, n° 5, p. 1265-72. https://archive-ouverte.unige.ch/unige:72647

157 hits

0 download

Update

Deposited on : 2015-05-18

Export document
Format :
Citation style :